Both EZH2 inhibitor GSK126 and molecular silencing of EZH2 can block Ang-II-induced atrial fibroblast activation, migration, and ECM production in mice, attenuate Ang-II-induced atrial enlargement and fibrosis, and reduce atrial fibrillation vulnerability [106]. The gene discussed is EZH2; the disease is atrial fibrillation.